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Abstract
Background: Aberrant activation of the canonical Wnt/b-catenin pathway occurs in almost all colorectal cancers and
contributes to their growth, invasion and survival. Phopholipase D (PLD) has been implicated in progression of colorectal
carcinoma However, an understanding of the targets and regulation of this important pathway remains incomplete and
besides, relationship between Wnt signaling and PLD is not known.
Methodology/Principal Findings: Here, we demonstrate that PLD isozymes, PLD1 and PLD2 are direct targets and positive
feedback regulators of the Wnt/b-catenin signaling. Wnt3a and Wnt mimetics significantly enhanced the expression of PLDs
at a transcriptional level in HCT116 colorectal cancer cells, whereas silencing of b-catenin gene expression or utilization of a
dominant negative form of T cell factor-4 (TCF-4) inhibited expression of PLDs. Moreover, both PLD1 and PLD2 were highly
induced in colon, liver and stomach tissues of mice after injection of LiCl, a Wnt mimetic. Wnt3a stimulated formation of the
b-catenin/TCF complexes to two functional TCF-4-binding elements within the PLD2 promoter as assessed by chromatin
immunoprecipitation assay. Suppressing PLD using gene silencing or selective inhibitor blocked the ability of b-catenin to
transcriptionally activate PLD and other Wnt target genes by preventing formation of the b-catenin/TCF-4 complex, whereas
tactics to elevate intracellular levels of phosphatidic acid, the product of PLD activity, enhanced these effects. Here we show
that PLD is necessary for Wnt3a-driven invasion and anchorage-independent growth of colon cancer cells.
Conclusion/Significance: PLD isozyme acts as a novel transcriptional target and positive feedback regulator of Wnt
signaling, and then promotes Wnt-driven anchorage-independent growth of colorectal cancer cells. We propose that
therapeutic interventions targeting PLD may confer a clinical benefit in Wnt/b-catenin-driven malignancies.
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Introduction
Colorectal cancer is one of the most common malignancies,
occurring in a significant percentage of the population. More than
80% of sporadic and hereditary colorectal cancers may be caused
by aberrations in the Wnt/b-catenin signaling pathway [1]–[3].
Thus, alterations in the Wnt/b-catenin pathway define a key event
in the pathogenesis of colon cancer. b-Catenin is a transcriptional
coactivator of T cell factor (TCF)/lymphoid enhancer factor (Lef)
transcription factors. b-catenin stability is regulated by a multi-
protein complex that includes adenomatous polyposis coli (APC),
glycogen synthase kinase 3b (GSK3b), and axin. Phosphorylation
of b-catenin by GSK3b targets b-catenin to ubiquitination and
proteasome degradation [4]. Thus, activation of the pathway
represses b-catenin degradation, resulting in nuclear accumulation
of b-catenin. In the nucleus, accumulation of TCF/b-catenin leads
to transcriptional activation of multiple target genes, which can
then contribute to development of cancer [5], [6]. Thus,
identification of direct targets of the Wnt/b-catenin signaling
pathway is potentially important to understanding the central role
of the Wnt/b-catenin/TCF dependent canonical pathway in
tumorigenesis.
Phospholipase D (PLD) catalyzes hydrolysis of phosphatidyl-
choline (PC) to generate phosphatidic acid (PA), which acts as a
second messenger in many physiological responses [7]. Two
mammalian PC-specific PLD isozymes designated as PLD1 and
PLD2 have been cloned. PLD has emerged as a critical regulator
of cell proliferation and survival whose dysregulation occurs
during development of a variety of human tumors [8]. Elevated
expression of PLD1 and PLD2 has been reported in colorectal
cancer tissues [9]; in particular, PLD2 expression level and its
association with clinicopathological features have recently been
investigated in colorectal carcinoma [10]. Expression levels of
PLD2 correlate significantly with tumor size and survival of
patients with colorectal carcinoma [10]. The PLD2 point mutation
has also been found in breast cancer [11]. Cells overexpressing
PLD isozyme enhance matrix metalloproteinase-2 expression and
tumor cell invasion and form metastases in syngeneic mice [12],
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progression of colorectal carcinoma, and could be a target for
cancer therapy. We have recently reported on significant co-
overexpression of PLD isozymes with b-catenin in human
colorectal cancer [14]. Using two RNA interference (RNAi)-based
loss-of-function screens, the oncogenes that modulate b-catenin-
dependent transcription and regulate colon cancer cell prolifera-
tion have been identified [15].
Among one of the genes identified in this screen was PLD1, and
suppression of PLD1 significantly inhibited both b-catenin
transcriptional activity and colon cancer cell proliferation. In the
present study, we demonstrate the action of PLD isozymes as novel
targets and positive feedback regulators of Wnt signaling. Thus,
identification of a Wnt-b-catenin-TCF-regulated PLD axis
provides new mechanistic insights into cancer.
Materials and Methods
Cell lines and reagents
Human colorectal cancer cells (HCT116, HCA-7, Colo-741,
RKO) and breast cancer cells (HS578T) were purchased from
ATCC (Manassas, VA) and were grown according to standard
protocols. Purified recombinant Wnt3a was purchased from R&D
Systems Inc. BIO was obtained from Calbiochem. LiCl, 1- or 3-
butanol, dioctanoyl PA, and 1-propranolol were purchased from
Sigma-Aldrich. PLD1 and PLD2 selective inhibitors were
purchased from Cayman chemical. Dual luciferase assay kits were
purchased from Promega.
Plasmids and small interfering RNA
Human PLD1 (pGL4-PLD1 Luc) and PLD2 (pGL4-PLD2 Luc)
promoter reporter plasmids contain 21.9 kb (21930/+1) and
2.6 kb (22180/+491) of upstream 59-flanking DNA linked to
luciferase reporter genes, respectively, and have been described
elsewhere [14]. We used the promoter of hPLD1 (pGL4-PLD1;
21930/+1), transcribed from exon 2, among two alternate
transcripts of PLD1 to be transcribed at two different transcription
sites (exon 1 and exon 2). The PCR-based method was used for
cloning of serially deleted PLD2 promoter constructs into the
pGL4-14b reporter vector at the Kpn I and Bgl II site. The
sequence of the oligonucleotides used as primers in PCR
amplifications is shown in Table S1.
Mutations of TCF-4 binding elements on the PLD2 promoter
were generated using the Quick Change Site-Directed Mutagen-
esis Kit, according to the manufacturer’s recommendations
(Stratagene; Table S2). TOPflash and FOPflash luciferase
plasmids containing multiple copies of TCF/LEF response
elements were used for measurement of TCF activity. Domi-
nant-negative TCF-4 (DN30 TCF-4) was kindly provided by
Dr. Tesshi Yamada (National Cancer Center Research Institute).
Constitutive active mutant of b-catenin (S37A b-catenin) and wild
type TCF-4 expression vectors were kindly provided by Dr. Bert
Vogelstein (Johns Hopkins University). shRNA for b-catenin was
kindly provided by Dr. H. Clevers (Utrecht, The. Netherlands).
SiRNAs for control, PLD1, and PLD2 were purchased from
Dharmacon Research Inc (Lafayette, Colo). siRNA sequences for
PLDs are as follows: human PLD1 (nucleotides, 1571 to 1591,
AAGGUGGGACGACAAUGAGCA) and human PLD2 (nucle-
otides, 1378 to 1396, ACAUAAAGGUGAUGCGUCA).
Transient Transfection and Reporter Gene Assay
Following the manufacturer’s instructions, expression plasmids
or siRNA were transiently transfected into cells using LipofectA-
mine Plus (Invitrogen) or Polyfect (Qiagen) reagents. Transfection
and luciferase assays were performed as previously described [16].
Relative luciferase activity was obtained by normalization of the
activity of firefly luciferase against activity of the internal control
renilla luciferase.
Immunoprecipitation and Western Blotting
Cell lysates were analyzed for immunoprecipitation and/or
immunoblot, as previously described [17]. Anti-a-tubulin (Sigma,
MO), anti-vimentin (Sigma, MO), anti-c-Myc (Santa Cruz, CA),
anti-b-catenin (Santa Cruz, CA), anti-NOS2 (Santa Cruz, CA),
anti-TCF-4 (Santa Cruz, CA), anti-b-catenin (BD Biosciences,
CA), anti-cycinD1 (BD Biosciences, CA), and anti-phospho-
GSK3b antibody (Cell signaling, MA) were purchased. The
polyclonal anti-PLD antibody that recognizes both PLD1 and
PLD2 was generated as previously described [18].
PLD activity assay
PLD activity was assessed by measurement of the formation of
[
3H] phosphatidylbutanol, the product of PLD-mediated trans-
phosphatidylation, in the presence of 1-butanol, as previously
described [17].
Quantitative RT-PCR
Total RNA (1 mg) was pretreated with DNase and used for
reverse transcription with M-MLV reverse transcriptase (Invitro-
gen). Real-time Q-PCR was performed on a Rotor-Gene RG-
6000A apparatus (Corbett Research): for 44 cycles of 94uC for
10 sec, 60uC for 10 sec, and 72uC for 15 sec. Reactions (20 ml)
included 2 ml of cDNA, target-specific primers, and the Quantitect
SYBR green PCR kit (QIAGEN). The temperature range for
analysis of melting curves was 55uCt o9 9 uC over 30 sec. Three
independent experiments were performed for each reaction in
triplicate. All data were normalized with GAPDH gene expression
values. See Table S3 for Q-RT-PCR primer sequences.
Animal and tissue preparation
Mice were provided with standard maintenance and a diet from
Dae Han Bio Link (Seoul, Korea). Animal studies were approved
and performed under guidelines of the Institute of Health
Guidelines for the Institutional Review Board of Pusan National
University (Busan, Korea). Twelve week-old male FVB mice
received intravenous injection with LiCl once each day for 2 days
at dose of 5 mg/kg. The control group was injected with the same
volume of phosphate-buffered saline (PBS). Forty-eight hrs after
LiCl injection, animals (n=3/group) were deeply anesthetized
with diethyl ether and decapitated, and the tissues were frozen
immediately in LN2 and stored at 270uC for immunoblotting.
Mice (n=3/group) also were anesthetized and then perfused
intracardially with 4% paraformaldehyde in PBS containing
0.34% L-lysine (Sigma). Following fixative perfusion, the tissues
were removed, placed in 4% paraformaldehyde solution at 4uC
overnight, and then transferred to a 30% sucrose solution. The
tissues were processed by coronal cryostat sectioning in Dulbecco’s
PBS solution containing 0.1% sodium azide using a freezing
microtome (MICROM, Germany).
Immunohistochemistry
Paraformaldehyde-fixed 4 mm paraffin sections of colon tissues
were autoclaved in 10 mM sodium citrate buffer (pH 6.0). After
blocking with 5% BSA and 1% normal goat serum in PBS,
sections were incubated with anti-b-catenin (BD transduction) and
PLD antibodies overnight at 4uC, followed by washing with PBS.
Subsequently, sections were incubated with Alexa fluor 488 or
PLD and Wnt Signaling
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1:200) at room temperature for 1 h, followed by washing with
PBS. After counterstaing with DAPI, and slides were mounted in
Permount
H (Fisher Scientific, USA). Two-color fluorescent image
for anti-PLD and b-catenin antibody staining were collected on a
Zeiss LSM 510 confocal microscope (Zeiss, Germany). Fluorescent
images were analyzed using Zeiss LSM image browser software
(Zeiss).
Chromatin immunoprecipitation (ChIP) assay
ChIP experiments were performed as previously described
[19], with minor modifications. HCT116 cells were used for
crosslinking with 1% paraformaldehyde in phosphate-buffered
saline (PBS) for 10 min. Cells were scraped and collected by
centrifugation. Cells were lysed in lysis buffer (50 mM Hepes,
pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1%
deoxycholate, and 1.0 mM protease inhibitor cocktail) and
sonicated for 20 sec 3 times. Normal mouse IgG, anti-b-catenin
or anti-HDAC1 antibody was added and incubated for 6 h at
4uC. Immnunocomplexes were extracted 3 times with 1% SDS,
0.1 M NaHCO3, and crosslinking was reversed by incubation at
65uC overnight. The saved chromatin input fraction was also
processed in the same manner. Samples were then digested with
DNase- and RNase-free proteinase K at 50uC for 4 h, and
extracted with phenol/chloroform/isoamylalcohol. DNA samples
were purified with Qiagen clean-up columns. The PLD2 or
NOS2 promoter region was analyzed by Q-RT-PCR using
specific primers (Table S4).
Cell Migration and Invasion Assays
Cells were added to Transwell membrane chambers (pore size,
12.0 mm; Corning). The number of cells that migrated through the
membrane to the lower chamber was counted after 24 hours. For
siRNA experiments, cells were seeded 24 hours after transfection
with siRNAs, and migration assays were performed for another
24 hours. For the invasion assays, Matrigel (1:5; BD) was added to
Transwell membrane chambers and incubated for 5 hours; cells
were then seeded. Extent of migration and invasion were
expressed as an average number of cells per microscopic field.
Anchorage-independent growth assay
Anchorage independent growth was measured using the CytoSe-
lect
TM 96-Well In Vitro Tumor Sensitivity Assay (Cell Biolabs, CA),
according to the manufacturer’s specifications. Anchorage indepen-
dent growth was examined insoftagar; 50 ml of base agar matrix was
added to the bottom of each well of a 96-well plate. Once the agar
was solid, 75 ml of cell suspension/soft agar matrix containing 3610
3
cells was layered onto the top, followed by 50 mlo f2 6 complete
medium with Wnt3a and/or inhibitors. After 10 days of incubation,
the agar matrix was solubilized, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide was added to each well. The
absorbance produced by formation of insoluble formazan product
by viable cells was recorded at 570 nm.
Statistical analysis
All experiments were independently performed at least three
times, with similar results. Data were analyzed by the Student’s t
test, and P,0.05 was considered statistically significant.
Results
Wnt signaling promotes expression of PLD isozymes
To examine the question of whether or not Wnt signaling
increases PLD expression, HCT116 colorectal cancer cells were
exposed to Wnt3a or Wnt3a mimetics (Figure 1). As determined
by immunoprecipitation and Western blot, expression of both
PLD1 and PLD2 was enhanced in a time-dependent manner
following exposure to purified recombinant Wnt3a (150 ng/ml)
(Figure 1A, upper panel). Anti-PLD antibody was generated
against C-terminal peptide of PLD1 in which 7 amino acids
among 12 amino acids were the same with that of PLD2, and
recognizes both PLD1 and PLD2 [18]. It was demonstrated that
HCT116 cells have mutations in b-catenin at Ser-45 and that this
Ser-45 mutant allele was not sufficient to support tumorigenesis of
HCT116 cells [20]–[22]. Thus, it is suggested that the b-catenin
pathway in HCT116 cells is not fully activated by the mutation,
and therefore can be stimulated by additional extracellular
messengers, such as Wnt signaling, resulting in further oncogenic
transformation. We then investigated the question of whether or
not Wnt signaling-induced PLD expression might be regulated at a
transcriptional level. Wnt3a enhanced the mRNA levels of PLD1
and PLD2 in a time-dependent manner (Figure S1). To exclude
that Wnt-dependent increase of PLD mRNA is only caused by
changes in mRNA stability, we performed a mRNA decay assay
using actinomycin D, which prevents transcription. The expres-
sion of PLD1 and PLD2 was increased over time in a comparable
fashion between Wnt-treated and control cells as analyzed by Q-
RT-PCR (Figure S2). Pretreatment with actinomycin D signifi-
cantly suppressed both basal and Wnt3a-induced PLD mRNA
levels (Figure S2). Thus, Wnt-dependent increase of PLD mRNA
is indeed due to elevated transcription. In order to further
strengthen our results, we determined the effect of blockade of
GSK-3b on PLD expression. LiCl and BIO are established
agonists that mimic the Wnt-signaling pathway, leading to
activation and stabilization of b-catenin [23], [24]. As analyzed
by immunoprecipitation and Western blot, LiCl (20 mM), BIO
(1 mM), and Wnt3a (150 ng/ml) significantly increased the
expression level of PLD isozymes (Figure 1B). Wnt mimetics also
increased the protein level of b-catenin, as well as expression of c-
Myc and NOS2, target genes of Wnt signaling. As analyzed by Q-
RT-PCR, Wnt signaling markedly elevated expression levels of
PLD mRNA (Figure 1C). Additionally, Wnt and its mimetics
significantly enhanced the promoter activity of both PLD1 and
PLD2 (Figure 1D); Wnt3a accompanied a significant increase in
gene expression from a TCF/LEF specific luciferase reporter
plasmid (TOPflash) used as a control. Moreover, we found that
Wnt3a increased expression levels of PLD isozymes in various
cancer cells, including colorectal cancer cells (HCA-7, RKO,
Colo-741) and breast cancer cells (HS578T) (Figure S3). To
observe the induction of PLD isozymes in response to Wnt
signaling, we chose cancer cells in which the status of the Wnt
pathway is normal. These cancer cells are known to express wild
type APC and b-catenin [25]–[29]. Thus, it is suggested that Wnt
signaling-induced PLD expression might be a general phenome-
non. Upregulation of PLDs expression by Wnt3a and Wnt
mimetics strongly implicated a central role for inhibition of
GSK3b and the canonical Wnt signalling pathway in Wnt-
mediated effects. Taken together, these results indicate that
induction of the PLD isozyme as a novel target of Wnt signaling
is regulated at both the transcriptional and post-transcriptional
levels.
LiCl induces expression of PLD isozymes in vivo
To further strengthen our results, we investigated the effect of
blockade of GSK3b on PLD expression in vivo. LiCl was injected
into mice, and expression of PLD was investigated in several
tissues using anti-PLD antibody which recognizes both PLD1 and
PLD2. We have reported on the specificity of the antibody to PLD
PLD and Wnt Signaling
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LiCl increased protein levels of both PLD1 and PLD2 in colon,
stomach, and liver tissues (Figure 2A). As a positive control, the
level of b-catenin and NOS2, as well as phosphorylation of
GSK3b, was increased in LiCl-injected tissues. A complementary
result with regard to expression of PLDs following application of
LiCl was also obtained by immunofluorescence in colon tissues
(Figure 2B). Nuclei were counterstained by DAPI. Whereas b-
catenin showed a membraneous staining pattern in PBS-injected
control colon, b-catenin was increased by LiCl in the cytoplasm
Figure 1. Wnt3a and GSK3b inhibitors increase expression of PLD isozymes in HCT116 colon cancer cells. (A) HCT116 cells were treated
with purified recombinant Wnt3a (150 ng/ml) for the indicated times, and the lysates were immunoprecipitated and immunoblotted with antibody
to PLD. b-catenin was analyzed by Western blotting using nuclear lysates (upper panel). Histograms show relative protein levels of PLD1 and PLD2,
which are normalized to the corresponding a-tubulin values (lower panel). (B-C) HCT116 cells were treated with Wnt3a (150 ng/ml), LiCl (20 mM), or
BIO (1 mM) for 24 h. (B) Protein level of PLDs was analyzed by immunoprecipitation and immunoblotting. c-Myc and NOS2 expression was analyzed
by Western blotting (upper panel). Histograms show relative protein levels of PLD1 and PLD2, which are normalized to the corresponding a-tubulin
values (lower panel). Data are representative of three independent experiments. (C) mRNA levels of the indicated genes were analyzed by Q-RT-PCR.
*P,0.05 versus vehicle. (D) The indicated promoter reporter plasmids were transfected and treated with Wnt3a, LiCl, or BIO for 12 h; luciferase activity
was then determined. *P,0.01 versus vehicle. Data represent the mean 6 S.D. of three independent experiments.
doi:10.1371/journal.pone.0012109.g001
PLD and Wnt Signaling
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both the cytoplasm and nucleus of cells in LiCl-injected colon as
b-catenin was increased (Figure 2B). Collectively, these observa-
tions indicate that expression of both PLD1 and PLD2 is enhanced
in tissues of LiCl-treated mice.
b-catenin and TCF-4 upregulate expression of PLD
isozymes
We examined the question of whether or not expression of
PLD isozymes is indeed transcriptionally activated by
b-catenin or TCF-4. As shown in Figure 3A, ectopic expression
of TCF-4 and a stable b-catenin mutant (S37A b-catenin),
which is insensitive to ubiquitination of b-catenin, enhanced
transcriptional activation of both PLD1 and PLD2. TCF-4 and
stable b-catenin mutant significantly increased gene expression
from a TCF/LEF specific luciferase reporter plasmid used as a
control. This induction was significantly decreased by addition
of a dominant negative (dn) TCF-4 expression vector (DN30
TCF-4) (Figure 3A). Moreover, analysis by immunoprecipita-
tion and immunoblot showed that ectopic expression of
b-catenin or TCF-4 increased endogenous protein levels of
PLD1 and PLD2 isozymes in HCT116 cells. TCF-regulated
genes, including c-Myc and NOS2, were also increased by
expression of b-catenin or TCF-4 (Figure 3B). Furthermore,
transfection of dnTCF-4 or depletion of b-catenin using
shRNA decreased the protein levels of both PLD isozymes
and Wnt target genes in HCT116 cells (Figure 3C). These
results indicate that expression of PLD isozymes is upregulated
by both b-catenin and TCF-4.
b-catenin and TCF-4 bind to the TBEs of the PLD2
promoter and enhance PLD2 expression
A polymorphism of the PLD2 gene has recently been associated
with prevalence of colorectal carcinoma [31]. Moreover, expres-
sion levels of PLD2 detected by real-time PCR using 97 colorectal
carcinoma tissues were significantly correlated with tumor size and
survival of patients with colorectal carcinoma; thus, it was
suggested that PLD2 expression level could be a prognostic
indicator in colorectal carcinoma [10]. Therefore, we attempted to
examine the regions that are responsible for Wnt/b-catenin/TCF-
4-induced PLD2 expression.
As shown in Figure 4A, the 22180/+491 PLD2 promoter was
transactivated by TCF-4 (4.6-fold) or S37A b-catenin (2.3-fold)
proteins. Sequential 59 deletions of the PLD2 promoter to
positions 21601, 21210, and 2784 did not affect TCF-4- or
S37A b-catenin-mediated transactivation of the PLD2 promoter
(TCF-4, 4.2-fold; b-catenin 2.2-fold activation of all mutants);
however, deletion of -380 regions significantly decreased TCF-4 or
Figure 2. LiCl increases expression of PLD isozymes in vivo. (A) Mice were intravenously injected with LiCl, as described in ‘‘Materials and
Methods’’. Lysates from various tissues were immunoprecipitated and immunoblotted with antibody to PLD recognizing both PLD1 and PLD2 (left
panel). Protein levels were analyzed by immunoblot using the indicated antibodies. Histograms show relative protein levels of PLD1 and PLD2, which
are normalized to the corresponding a-tubulin values (right panel). (B) Paraffin sections of colon tissues were subjected to immunofluorescence
analyses using anti-b-catenin (Alexa fluor 488; green) and PLD (Alexa fluor 555; red) antibody. Tissues were monitored using Zeiss LSM 510 confocal
microscope. Microscopy fields were observed at 6650 magnification. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0012109.g002
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suggested that putative TCF binding element (TBE) at positions
2784 , 2380 may be essential for PLD2 gene regulation by
TCF-4 and b-catenin.
As shown in Figure 4B, sequence analysis of the 59-flanking
sequence of the PLD2 gene identified two putative TBEs
(designated as TBE1 and TBE2). TBE1 (ATGAAAG) is located
2512 b upstream, and contains a nearly inverted match with the
Figure 3. b-catenin and TCF-4 enhance the promoter activities and protein levels of PLD isozymes. (A) HCT116 cells were co-transfected
with pGL4-PLD or TOP/FOP reporters and the indicated expression vectors. *P,0.01 versus mock; {P,0.05 versus S37A b-catenin/TCF-4. (B) Cells were
transfected with either the TCF-4 or b-catenin expression vector, and lysates were immunoprecipitated or immunoblotted with the indicated
antibodies (upper panel). Histograms show relative protein levels of PLD1 and PLD2, which are normalized to the corresponding a-tubulin values
(lower panel). (C) Cells were transfected with DN30 TCF-4 or shRNA for b-catenin. Lysates were analyzed by immunoprecipitation or Western blot
using the indicated antibodies (upper panel). Protein expression was quantitated by densitometer analysis. Histograms show relative protein levels of
PLD1 and PLD2, which are normalized to the corresponding a-tubulin values (lower panel). Data are representative of three independent
experiments.
doi:10.1371/journal.pone.0012109.g003
PLD and Wnt Signaling
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TBE2 (CTTTCAT) was located 2497 b upstream and nearly
matched the consensus sequence (Table S2) [33].
To examine the functional importance of the TBE motif in
regulation of PLD2 gene transcription, site-directed mutation of
TBE sites was generated in the context of a PLD2 promoter.
Mutation in the TBE1 or TBE2 site significantly decreased
Wnt3a-induced PLD2 promoter activity in HCT116 cells
(Figure 4C). Mutations of both the TBE1 and TBE2 sites
(TBE1/2) dramatically suppressed Wnt3a-stimulated PLD2 pro-
moter activity. Moreover, TCF-4 and/or b-catenin-induced PLD2
promoter activity was also abolished when TBE1 and TBE2 were
mutated (Figure 4D). These data suggest that the PLD2 promoter
is a target of the TCF/b-catenin complex via its consensus TBE.
Furthermore, we then performed a chromatin immunoprecip-
itation (ChIP) assay in HCT116 cells to confirm in vivo binding of
b-catenin/TCF-4 to the PLD2 promoter. DNA-b-catenin/TCF-4
complexes were immunoprecipitated with antibodies shown in
Figure 4E, followed by reversal of cross-linking and Q-RT-PCR
using primers flanking both TBE1 and TBE2, which are located in
proximal position to each other. As shown in Figure 4E, purified
recombinant Wnt3a enhanced binding of b-catenin/TCF-4 to
both TBEs of the PLD2 promoter. These results are comparable
with those of the promoter assay using mutagenesis. Wnt signaling
targets b-catenin to chromatin for removal of the corepressor
HDAC1 (histone deacetylase 1) [34]. As expected, Wnt3a
significantly suppressed binding of b-catenin to two TBEs of the
PLD2 promoter after the ChIP assay, using anti-HDAC1
antibody. Moreover, we found that TCF binding sites on the
PLD2 promoter are conserved across species (Figure 4F). Taken
together, these data demonstrate that the PLD2 gene is a direct
transcriptional target of b-catenin/TCF signaling in vivo.
PLD isozymes are required for formation of the b-
catenin/TCF-4 complex and promotion of b-catenin/TCF
transcriptional activity
We investigated the question of whether or not Wnt signaling-
induced PLDs upregulation might modulate b-catenin-dependent
TCF transcriptional activity via a positive feedback loop. Ectopic
expression of a constitutive active mutant of b-catenin increased
TCF transcriptional activity in HCT116 colon cancer cells
(Figure 5A). Selective PLD inhibitors have recently been
developed [35], [36]. Thus, we examined the effect of PLD
isoform-selective inhibitor on TCF activity. Interestingly,
VU0155069, a selective PLD1 inhibitor and VU0285655-1, a
selective PLD2 inhibitor [35], abolished b-catenin/TCF-4 activity
(Figure 5A). Moreover, depletion of PLD1 or PLD2 using siRNA
abolished Wnt3a-induced b-catenin/TCF transcriptional activa-
tion (Figure 5A). Reduction of PLD isozyme by siRNAs was
analyzed by Q-RT-PCR and immunoprecipitation/immunoblot
(Figure S4). Since the integrity of the b-catenin/TCF complex is
required for proper transcriptional activity, we examined the
possibility that Wnt-induced PLDs upregulation could enhance the
association of b-catenin with TCF-4. In Wnt3a-treated cells, a
substantial level of b-catenin was associated with TCF-4, while, in
contrast, depletion of PLD1 or PLD2 isozyme significantly
disrupted Wnt-induced b-catenin/TCF-4 association, without
detectable modulation of b-catenin and TCF-4 levels (Figure 5B).
Moreover, depletion of PLD1 or 2 blocked expression of Wnt3a-
induced target genes, including c-Myc, Cyclin D1, NOS2, and
vimentin (Figure 5B). Pretreatment with PLD1 or PLD2 selective
inhibitor also decreased Wnt3a-induced b-catenin/TCF-4 inter-
action and Wnt3a target genes (Figure 5C), suggesting that PLD
activity is required for these effects. We also found that treatment
with Wnt3a (150 ng/ml) for 20 h stimulated PLD activity
(Figure 5D). This activity dependency was further confirmed by
treatment of cell-permeable dioctanoyl-PA and accumulation of
endogenous PA by treatment of 1-propranolol, a PA phosphatase
inhibitor (Figure 5E). To further confirm the involvement of PLD
activity in the interaction, HCT116 cells were pretreated with
either 1-butanol or 3-butanol, and then stimulated with Wnt3a. 1-
Butanol was used to block PA production by PLD by virtue of
phosphatidylbutanol formation through the transphosphatidyla-
tion reaction. 1-butanol, but not 3-butanol, an inactive analogue
for PLD-mediated PA formation, significantly disrupted Wnt-
induced b-catenin/TCF-4 association and expression of Wnt
target genes without detectable modulation of b-catenin and TCF-
4 levels (Figure S5). These results suggest that Wnt-induced PLD
upregulation is required for b-catenin/TCF-4 transcriptional
activation by increasing formation of the b-catenin/TCF-4
complex.
PLD isozymes mediate anchorage-independent growth,
migration, and invasion in concert with the Wnt/b-
catenin/TCF-dependent pathway
Next, we examined the question of whether or not PLD
isozymes play a role in determining the motile, invasive, and
tumorigenic capacity of human colon cancer cells. Stimulation of
recombinant Wnt3a increased migration and invasion of HCT116
cells. Depletion of PLD1 or 2 suppressed Wnt3a-induced
migratory and invasive activity (Figure 6A and B). Transfection
of control siRNA had no effect. Using Q-RT-PCR, we observed
reduction of PLD isozyme by siRNAs (Figure S4). These data
suggest that the effect of Wnt signaling on cell migration and
invasion is at least mediated via PLD isozymes. Using an in vitro
tumor sensitivity assay, we further investigated the question of
Figure 4. b-catenin/TCF-4 specifically binds to the TBEs of the PLD2 promoter and enhances PLD2 expression. (A) Deletion analysis of
pGL4-PLD2 in HCT116 cells. A schematic representation of pGL4-PLD2 reporter constructs is shown. Cells were cotransfected with pGL4-PLD2 and the
indicated expression vectors, followed by determination of luciferase activity. (B) Diagrammatic representation of the 22180 to +491 region of the
human PLD2 promoter. Numbers above the lines refer to the transcription start site of the PLD2 gene (+1). Two putative binding sites for TCF-4 are
indicated on the sequence (the arrows indicate the direction). (C) HCT 116 cells were transfected with the luciferase reporter plasmid containing the
wild type (wt) PLD2 promoter, one or double TBE mutant forms (mt) of PLD2 promoter, and treated with Wnt3a (150 ng/ml) or BIO (1 mM). Luciferase
activities were measured. *P,0.05 versus wtTBE/Wnt3a; {P,0.01 versus wtTBE/BIO. (D) Cells were co-transfected with the indicated expression
vectors, along with the wt or TBE mutant forms of the PLD2 promoter. Luciferase activities were measured. *P,0.05 versus transfected with wtTBE/b-
catenin; {P,0.05 versus wtTBE/TCF4; **P,0.05 versus transfected with wtTBE/b-catenin/TCF4. (E) Arrows indicate position of primers used in the ChIP
experiment. The ChIP assay was performed using preimmune IgG, anti-b-catenin, or anti-HDAC1 antibody and analyzed by Q-RT-PCR. As a positive
control, ChIP analysis of the NOS2 promoter containing TBE was performed. *P,0.05 versus b-catenin/vehicle; {P,0.05 versus HDAC1/vehicle. Data
are representative of four independent experiments. (F) Schematic diagram for comparison of TBEs on PLD2 promoter regions from various species.
TCF-4 binding elements in 59 flanking regions of the human PLD2 transcriptional start site (TSS) were compared with those of the genomes from 4
different species. A core motif, CTTTG(A/T)(A/T) [or the complementary sequence (A/T)(A/T)CAAAG] of TCF binding sequences on PLD2 promoter is
highly conserved across species.
doi:10.1371/journal.pone.0012109.g004
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PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12109whether or not PLD isozyme is required for Wnt/b-catenin-
mediated tumorigenic effects. Treatment with Wnt3a in HCT116
cells increased anchorage-independent colony growth, whereas
depletion and selective inhibitor of the PLD isoform significantly
suppressed Wnt3a-driven anchorage-independent growth
(Figure 6C). We also found that S37A b-catenin-induced
anchorage-independent growth was abolished by PLD depletion
and PLD isoform selective inhibitor (data not shown). Addition-
ally, ectopic expression of PLD1 or PLD2 enhanced anchorage-
independent colony growth, which was significantly abolished by
dominant negative TCF-4 (DN30 TCF-4), indicating that Wnt
signaling is required for a PLD-induced tumorigenic effect
(Figure 6D). These results suggest that PLD isozyme contributes
to the anchorage-independent tumorigenic effect in concert with
the Wnt/b-catenin/TCF-mediated pathway.
Discussion
In the present study, we demonstrate that PLD isozyme is a
novel downstream target and positive feedback regulator of the
Wnt/b-catenin signaling pathway. Activity of b-catenin and TCF-
4, key components of the Wnt signaling pathway, is frequently
deregulated in colon cancers, resulting in activation of genes whose
dysregulation has significant consequences on tumor development.
Therefore, identification of the target genes of Wnt signaling is
important for understanding b-catenin-mediated carcinogenesis.
Identification of PLDs as targets of the b-catenin/TCF-4 complex
further emphasizes the importance and complexity of the Wnt
pathway in physiologic and pathologic processes.
Exploration of the potential roles of PLD isoforms in tumor
biology has only just begun. We have reported that stable
overexpression of either PLD1 or PLD2 in fibroblasts causes
transformation and enhancement of tumor formation [18]. In
another study, overexpression of PLD2 resulted in transformation
of fibroblasts overexpressing the epidermal growth factor receptor
or c-Src [37]. Elevated expression of PLD1 and PLD2 has been
reported in colorectal cancer tissues [9]. One interesting report
indicates that a polymorphism in the PLD2 gene is associated with
increased risk of colorectal cancer [31]. Findings from a recent
study showed a significant association of PLD2 expression level
with tumor size (P,0.05) and survival of patients with colorectal
carcinoma (P,0.05) [10]. Moreover, cells overexpressing PLD
isozyme enhance tumor cell invasion and form metastases in
syngeneic mice [12], [13]. The PLD2 point mutation has been
found in breast cancer cells [11], and PLD2 overexpression
confers a survival signal attributed to an increase in basal mTOR
activity [38]. We recently reported on statistical correlation of
PLD levels and b-catenin in clinical samples, as analyzed by
immunohistochemistry using tissue microarray [14].
In the present study, Wnt3a and mimicking of Wnt signaling
through LiCl and BIO resulted in induction of both PLD1 and
PLD2 in a variety of cancer cells. Moreover, LiCl induced
expression of PLD isozymes in several tissues from mice,
suggesting its physiological relevance in vivo.
Transfection of dominant negative TCF-4 or shRNA to b-
catenin abrogated endogenous PLD1 and PLD2 protein expres-
sion, which further confirms the specificity of this pathway in
regulation of PLDs. Transactivation of genes by the b-catenin/
TCF-4 complex involves its binding to a consensus TBE in the
promoter region of the target genes [32]. Using site-directed
mutagenesis and the ChIP assay, we were able to define two
functional TCF binding sites on the PLD2 promoter, suggesting
that the PLD2 gene is a direct transcriptional target of b-catenin/
TCF signaling. Identification of active TBE sites in the present
study further expands understanding of the critically important
mechanisms in place for regulation of PLD2 transcription.
Recently, Firestein et al. [15] have identified genes that both
modulate b-catenin activity and are essential for colon cancer cell
proliferation using two RNAi-based loss-of-function screens.
Among one of the genes identified in this screen was PLD1.
Moreover, we also found that TCF binding elements existed in the
promoter region of PLD1 gene and PLD1 also promotes Wnt
signaling through TCF4 transcriptional activation.
Other signaling cascades can also impinge on expression of
PLD. For instance, tumor promoters, such as phorbol myristate,
stimulate selective PLD1 expression via the NFkB signaling
pathway [14]. Ewing’s sarcoma fusion protein, EWS/Fli, has been
reported to induce selective PLD2 expression by binding to the
ETS domain of the PLD2 promoter [39]. Therefore, it is likely
that several signaling cascades can therefore contribute to control
of PLD gene expression, which might be used to a differing extent
in distinct tumor types.
Being an enzyme, PLD activity can be tightly regulated by
different ways: by PKC, Rho GTPases, PIP2 etc. That is why the
transcriptional and translational regulation of the PLD expression
may be not so important for activity of the enzyme. But post-
transcriptional regulation, i.e. regulation of the PLD activity may
be more crucial for the cells, considering some potential
therapeutical interventions using targeting PLD. Since elevation
of PLD expression contribute to increase of its enzymatic activity,
studies for regulation of PLD expression are also important.
Interestingly, our data demonstrate that Wnt-induced PLDs
upregulation promotes b-catenin/TCF transcriptional activity by
increasing formation of the b-catenin/TCF-4 protein complex,
and then enhances expression of TCF-4-dependent genes. PLD
activity was required to increase formation of the complex and
Wnt3a target gene expression.
We have recently reported on statistical correlation of PLD and
b-catenin levels in clinic samples, as analyzed by immunohisto-
chemistry using tissue microarray [14]. Co-overexpression of PLD
and b-catenin was detected in 64 (52%) of 122 colorectal cancers
[14], indicating in vivo presence of the Wnt-b-catenin-PLD positive
feedback loop.
PLD protein itself does not appear to directly regulate the
interaction between b-catenin and TCF-4. PLD activity might
modulate the expression level of protein, which can affect
association of b-catenin with TCF and b-catenin/TCF-4
activity. Several proteins such as Chibby, Groucho, FOXO3a
Figure 5. PLD isozyme is required for formation of the b-catenin/TCF-4 complex and promotion of b-catenin/TCF transcriptional
activity. (A) After HCT116 cells were co-transfected with TOP/FOP reporters, S37A b-catenin, or siRNA for PLDs, cells were treated with or without the
indicated dose of VU0155069 or VU0285655-1; TCF activity was then determined. *P,0.05 versus Mock; **P,0.05 versus S37A b-catenin; {P,0.05
versus S37A b-catenin-siRNA. HCT116 cells were transfected with siRNAs for PLD (B) or pretreated with 10 mM of VU0155069 or VU0285655-1 (C), and
then stimulated with Wnt3a (150 ng/ml) for 20 h. (D) HCT116 cells were labeled with [
3H] myristate and treated with Wnt3a (150 ng/ml) for 12 h. PLD
activity was measured as dsescribed in Materials and Methods. *P,0.05 versus vehicle. (E) HCT116 cells were treated with the indicated dose of PA or
1-propranolol for 24 h. Association of TCF-4 with b-catenin was analyzed by immunoprecipitation and immunoblot using the indicated antibodies.
Protein levels were determined by immunoprecipitation or immunoblotting using the indicated antibodies. Interaction levels or protein expression
were quantitated by densitometer analysis. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0012109.g005
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b-catenin to TCF [40]–[43], might be negatively regulated by
PLD1. In addition, it could not also be excluded the possibility
that Wnt-induced PLD upregulation may induce a protein(s) that
somehow stimulates formation of a transcriptionally active
complex between TCF-4 and b-catenin. It has recently been
reported that glycophosphatidylinositol (GPI)-specific PLD can
promote Wnt signaling by relieving the retention of Wnt in the
endoplasmic reticulum (ER) [44]. Since PC-specific PLD
described in our study cannot hydrolyze GPI structure, it is
not known whether PC-PLD would directly regulate Wnt
signaling by relieving the retention of Wnt in the ER. However,
relieving the retention of Wnt in the ER by PLD could be
another mechanism by which PLD modulates Wnt signaling.
Further study is needed for identification of mechanisms of PLD-
mediated Wnt signaling or b-catenin/TCF interaction in other
aspects.
Many of the components of Wnt/b-catenin signaling that have
been studied may serve as potential targets for therapeutic agents,
and blockade of Wnt/b-catenin signaling may lead to new
treatment strategies. For example, chemopreventive agents, such
as nonsteroidal anti-inflammatory drugs and curcumin, have been
Figure 6. PLD isozyme mediates anchorage-independent growth, migration, and invasion in concert with the Wnt/b-catenin/TCF-
dependent pathway. (A–B) HCT116 cells were transfected with or without siRNA for PLD1 or PLD2, and then seeded in Matrigel-coated invasion
chambers or migration chambers and stimulated with purified recombinant Wnt3a (150 ng/ml) for 24 h. The extent of invasion (A) and migration (B)
were expressed as an average number of cells per microscopic field. *P,0.01 versus vehicle; {P,0.05 versus Wnt3a/control-siRNA. (C) HCT116 cells
were transfected with siRNA for PLD1 or PLD2, suspended in agar matrix, and treated with or without 10 mM of VU0155069 or VU0285655-1 and
treated with Wnt3a (150 ng/ml). Following 10 days incubation, the anchorage-independent growth assay was performed as described in the
Materials and Methods section. *P,0.05 versus Mock; **P,0.05 versus Wnt3a; {P,0.05 versus Wnt3a/control-siRNA. (D) PLD1 or PLD2 mediates
anchorage-independent growth via Wnt signaling. HCT116 cells were transfected with the indicated expression vectors and an anchorage-
independent growth assay was performed. *P,0.05 versus Mock; {P,0.05 versus PLD1; {{P,0.05 versus PLD2. Data are representative of three
independent experiments.
doi:10.1371/journal.pone.0012109.g006
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inhibitor that suppresses binding of TCF-4 to b-catenin could be
very valuable as a new chemopreventive drug in treatment of
certain forms of cancer.
Activation of the Wnt/b-catenin pathway can result in changes
in epithelial cell morphology (eg, epithelial-mesenchymal transi-
tion) and can enhance proliferation, migration, and invasion
[46]–[48]. We show here that such effects on motility and invasion
of Wnt/b-catenin signaling in colon carcinoma cells are mediated
by PLD isozymes. Our data suggest that PLD activity is required
for tumorigenic effect, such as anchorage-independent growth in
concert with the Wnt/b-catenin/TCF-mediated pathway. We
recently reported that PLD enhances expression of the MMP-2
gene by increasing the DNA binding activity of NFkB and Sp1,
and then promotes glioma cell invasion [13]. Thus, it is speculated
that PLDs can promote tumour phenotype independence of TCF-
induced genes.
The present finding describing PLD isozyme as a new target
and positive regulator of Wnt/b-catenin further expands under-
standing of the existing and rather extensive regulatory network of
the Wnt signaling pathway. Accordingly, therapeutic interventions
that target the PLD enzymatic activity using PLD inhibitor may be
of clinical value in colorectal cancer. Future studies are warranted
for further examination of the role of the Wnt/b-catenin/PLD
pathway in cancer development.
Supporting Information
Figure S1 Wnt3a increases in a time dependent manner mRNA
levels of PLD isozymes in HCT116 cells. The purified recombi-
nant Wnt3a (150 ng/ml) was treated in HCT116 cells for the
indicated times, and the expression level of PLD isozymes were
analyzed by Q-RT-PCR. *P,0.05 compared with non-treatment.
Data represent the mean 6 S.D. of three independent
experiments.
Found at: doi:10.1371/journal.pone.0012109.s001 (0.03 MB
PDF)
Figure S2 Wnt-dependent increase of PLD mRNA is due to
elevated transcription. HCT116 cells were pretreated with
actinomycin D (5 mg/ml) and treated with Wnt3a (150 ng/ml)
for the indicated times and then PLD mRNA levels were analyzed
by Q-RT-PCR. *P,0.05 compared with non-treatment; **P,
0.05 compared with Wnt3a. Data represent the mean 6 S.D. of
three independent experiments.
Found at: doi:10.1371/journal.pone.0012109.s002 (0.04 MB
PDF)
Figure S3 Wnt3a increases mRNA levels of PLD isozymes in a
variety of cancer cells. HCA-7, Colo-741, RKO and HS578T cells
were stimulated by Wnt3a (150 ng/ml) for 12 h. Expression of
PLD isozymes were analyzed by Q-RT-PCR. *P,0.05 versus
vehicle. Data represent the mean 6 S.D. of three independent
experiments.
Found at: doi:10.1371/journal.pone.0012109.s003 (0.04 MB
PDF)
Figure S4 Effect of PLD siRNAs on expression of PLD
isozymes. HCT116 cells were transfected with siRNAs for control
or PLD isozyme and the expression of PLD isozymes was analyzed
by Q-RT-PCR and immunoprecipitation/immunoblotting using
antibody to PLD. *P,0.05 versus control-siRNA.
Found at: doi:10.1371/journal.pone.0012109.s004 (0.08 MB
PDF)
Figure S5 PLD activity is required for Wnt-induced b-catenin/
TCF-4 association. HCT116 cells were pretreated with 1- or 3-
butanol (0.6%) and stimulated with Wnt3a (150 ng/ml) for 24 h.
Association of TCF-4 with b-catenin was analyzed by immuno-
precipitation and immunoblot using the indicated antibodies.
Protein levels were determined by immunoprecipitation or
immunoblotting using the indicated antibodies. Interaction levels
or protein expression were quantitated by densitometer analysis.
Data are representative of three independent experiments.
Found at: doi:10.1371/journal.pone.0012109.s005 (0.08 MB
PDF)
Table S1 Primer sets for deletion constructs of the hPLD2
promoter region.
Found at: doi:10.1371/journal.pone.0012109.s006 (0.03 MB
DOC)
Table S2 Consensus TBE in the PLD2 promoter.
Found at: doi:10.1371/journal.pone.0012109.s007 (0.04 MB
DOC)
Table S3 Primer sets for Q-RT-PCR.
Found at: doi:10.1371/journal.pone.0012109.s008 (0.04 MB
DOC)
Table S4 Primer sets for ChIP assay.
Found at: doi:10.1371/journal.pone.0012109.s009 (0.03 MB
DOC)
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